Jul. 31 at 9:19 PM
$CDT PURE COMEDY...
On June 3, 2025, the Company entered into the Joint Development Agreement with Manoira which granted Manoira a non-exclusive, non-transferable, non-sublicensable, fully paid-up, royalty-free license to the intellectual property rights related to the pharmaceutical compounds known individually and together as AZD1656 and AZD5658 (the “Conduit Assets”).
In connection with
$500,000 to be paid by the Company to Manoira, the Company issued 154,799 shares.
Manoira is considered to be a related party of the Company, as Dr. Andrew Regan, Chief Executive Officer of Conduit and member of Conduit’s board of directors, is also the sole director of Manoira. In addition, Manoira is an entity controlled by Dr. Andrew Regan.
